-+ 0.00%
-+ 0.00%
-+ 0.00%

Citizens Maintains Market Outperform on Crinetics Pharmaceuticals, Lowers Price Target to $96

Benzinga·03/02/2026 14:26:55
Listen to the news
Citizens analyst Jonathan Wolleben maintains Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Market Outperform and lowers the price target from $105 to $96.